SEC Form 4 · accession 0001171843-16-009007
Xenon Pharmaceuticals Inc. · XENE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Raymond Winquist
Officer — Head, Translational Research
Period of report
Apr 4, 2016
Accepted (ET)
Apr 4, 2016 · 6:58 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001582313
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $7.10 | Apr 4, 2016 | A | 35,000 | A | — | Apr 3, 2026 | Common Shares | 35,000 | 35,000 | D |
Explanation of responses
- F1Vesting 25% on April 4, 2017, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month.